A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

NCT00486759 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

787

Enrollment

INDUSTRY

Sponsor class

Stopped Due to an unfavorable benefit/risk ratio.

Conditions

B-cell Lymphoma

Interventions

DRUG: Bevacizumab
DRUG: Rituximab
DRUG: CHOP
DRUG: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]